A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled phase Ⅲ clinical study evaluating the
efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed
hyperlipidemia.